KELLIE BLACKWELL: Open Payments
NPI 1104053891 · ABINGDON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$832 in 9 payments from 6 companies in 2025. Trend: 2023 $13 · 2024 $499 · 2025 $832
Food & beverage: $832
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 3 | $188 |
| Dexcom, Inc. | 2 | $147 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Novo Nordisk Inc | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $121 |
Products named: FREESTYLE LIBRE 3, BREZTRI, DEXCOM G7 GSS (161), FANAPT, Ozempic, CAPLYTA, Dexcom G6 Transmitter.
Industry payments across VA — which companies pay providers there.
